Anticoagulation and AF: Emerging Insights

Slides:

Advertisements

Similar presentations

Anticoagulation for Atrial Fibrillation: Who, When, and How?

Advertisements

The GARFIELD Registry is funded by an unrestricted research grant from Bayer Pharma AG Lessons Beyond Atrial Fibrillation: Focus on.

ARCTIC investigators COI D ISCLOSURE FOR D R. M ONTALESCOT : Research Grants to the Institution or Consulting/Lecture Fees from Abbott Vascular, Astra-Zeneca,

The Capital Campaign. A Campaign Is An organized, intensive fundraising effort to secure gifts and pledges – beyond the existing level – for clearly identified.

PubMed was searched for randomized clinical trials published between 2007 and 2012 in the New England Journal of Medicine (NEJM) Trials were included if.

The GARFIELD Registry is funded by an unrestricted research grant from Bayer Pharma AG Alexander G G Turpie Professor Emeritus of.

Alberta’s Caring for Diabetes (ABCD) Project A Chronic Disease Management Initiative Jeffrey Johnson, PhD Canada Research Chair in Diabetes Health Outcomes.

Epidemiologic International Day For the Evaluation of Patients at Risk for Venous Thromboembolism in the Acute Hospital Care Setting Sponsored by an unrestricted.

On behalf of the TRILOGY ACS Investigators Prasugrel versus clopidogrel for patients with unstable angina/non-ST-segment elevation myocardial infarction.

Henry C. Ginsberg, MD College of Physicians & Surgeons, Columbia University, New York For The ACCORD Study Group.

Optimal Method and Outcomes of Catheter Ablation of Persistent AF: The STAR AF 2 Trial Atul Verma, Jiang Chen-yang, Tim Betts, John Radcliffe, Jian Chen,

Understanding Risk Professor Dan Atar, MD, FESC Dept. of Cardiology

The GARFIELD Registry is funded by an unrestricted research grant from Bayer Pharma AG Case discussion The patient caught between.

2014. Diamond Members  Alexion  Bristol Myers Squibb  Cardinal Health  Eisai, Inc.  Foundation Medicine  Genomic Health  McKesson  MedImmune.

Alexander GG Turpie On behalf of Kenneth A Bauer, Scott D Berkowitz, Fred D Cushner, Bruce L Davidson, Michael Gent, Louis M Kwong, Michael R Lassen, Paul.

Pharmaceutical Industry and Boehringer Ingelheim Paul Fonteyne Executive Vice President Head of Marketing & Sales, Prescription Medicines Pharmaceutical.

How Much AF is Too Much AF? Do I Initiate Anticoagulation Based on AF Detected on Device Monitoring? Kenneth W. Mahaffey, MD, FACC Professor of Medicine,

Joan A Stelmack, O.D., MPH Abbreviated Biography.

Global Variations in the 1-year Rates of Death and Stroke in Patients Presenting to the Emergency Department with Atrial Fibrillation Results from the.

1 Objectives, design and initial results from Phase I Nils Schoof Corp. Dept. Global Epidemiology, Boehringer Ingelheim GmbH.

2008© COPYRIGHT Thrombosis and Hemostasis Centers Research and Prevention Network Centers for Disease Control & Prevention Thomas L. Ortel, M.D., Ph.D.

Improving Access and Quality Use of Medicines in Palliative Care within National Drug Policy, Regulatory, and Funding Frameworks Debra Rowett, Tania Shelby-James,

Pharmacological thromboprophylaxis Professor Ajay Kakkar Barts and the London School of Medicine Thrombosis Research Institute, London, UK.

CHARISMA: The “CAPRIE-like” Cohort Deepak L. Bhatt MD, FACC, FSCAI, FESC, FACP Associate Director, Cleveland Clinic Cardiovascular Coordinating Center.

Managing Patients Who Cannot Take Anticoagulants Kenneth W. Mahaffey, MD, FACC Professor of Medicine, Cardiology Faculty Associate Director, DCRI Director,

The third international stroke trial (IST-3) effect of thrombolysis on outcomes at 18 months in 2348 patients in long-term follow- up cohort The IST3 collaborative.

NCEH/ATSDR Office of Tribal Affairs Annabelle Allison Environmental Health Scientist Office of Tribal Affairs National Center for Environmental Health.

17:00 – 19:00 | Sunday, 30 June, 2013 Session Room 3 Kuala Lumpur Convention Centre (KLCC) Kuala Lumpur, Malaysia Chair: Nicholas Paton.

Presented by Renato D. Lopes, MD, PhD, Duke Clinical Research Institute, Duke University, USA for the ARISTOTLE investigators. Efficacy and Safety of Apixaban.

The GARFIELD Registry is funded by an unrestricted research grant from Bayer Pharma AG Closing Remarks Jean-Pierre Bassand, MD, FESC,

Advisory Forum, July 2005 Outcome of the first retreat of ECDC Management Team (EXC) 4-5 July 2005 Krägga Herrgård Zsuzsanna Jakab Director ECDC.

Anonymous | Secure | User friendly

REPENTURN July 5, 2015 REPENTURN REPENTURN REPENTURN.

Antithrombotic Therapy in Peripheral Artery Disease Copyright: American College of Chest Physicians 2012 © Antithrombotic Therapy and Prevention.

Antithrombotic and Thrombolytic Therapy for Valvular Disease Copyright: American College of Chest Physicians 2012 © Antithrombotic Therapy and Prevention.

Treatment and Prevention of Heparin- Induced Thrombocytopenia Copyright: American College of Chest Physicians 2012 © Antithrombotic Therapy and Prevention.

Prevention of Venous Thromboembolism in Orthopedic Surgery Patients Copyright: American College of Chest Physicians 2012 © Antithrombotic Therapy.

Antithrombotic and Thrombolytic Therapy for Valvular Disease Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest.

Γεώργιος Ντάιος Παθολογική Κλινική, Πανεπιστήμιο Θεσσαλίας Διαχείριση αντιπηκτικής αγωγής εν όψει προγραμματισμένων επεμβατικών πράξεων.

1 Continuing Medical Education Grants and Sponsorships Name of RecipientProgram NameProgram DescriptionAmount University of CincinnatiPreventing Stroke.

EWOLUTION: 3-months outcome of Left Atrial Appendage Closure with the WATCHMAN device in Europe Thrombus at the device, leakage at follow-up, device embolisation,

The First 400 Patients PROSPECT Meeting June 13, 2016 Jennie Johnstone, MD, PhD, FRCPC St. Joseph’s Health Center Public Health Ontario.

Jim Bland Executive Director, CRIX International

Clinical Trial Design for Second Generation TAVI - Academic View

Identifying patients with atrial fibrillation and "truly low" thromboembolic risk who are poorly characterized by CHA2DS2-VASc: Superior performance of.

Y&H Atrial Fibrillation Stroke Prevention Programme

Treatment and Prevention of Heparin-Induced Thrombocytopenia

Addressing the Challenges in Primary and Secondary Stroke Prevention

ARCTIC-INTERRUPTION 2-year- Versus 1year Duration of Dual-Antiplatelet Therapy After DES implantation The randomized ARCTIC-Interruption Study JP Collet.

International prospective observational StudY on iNtrAcranial PreSsurE in intensive care (ICU) The SYNAPSE-ICU Study ClinicalTrials.gov Identifier: NCT

The EUROMAX trial is supported by The Medicines Company

Has acute myocardial infarction mortality hit rock bottom

The ANTARCTIC investigators

-LIVE Global Activities-

Closing remarks Professor Priscilla Harries Head Of Department- Clinical Sciences Brunel University London NWLondon Healthcare Symposium 21st September.

US Guidelines US Guidelines Low-risk Patients.

Selecting NOACs for High-Risk Patients

Assessing the Risk for Stroke in Patients With Atrial Fibrillation

Applying Real-World Evidence in Atrial Fibrillation Into Clinical Care:

TAVR and the Risk of Thrombosis

Improving Care for Older People in Acute Care

The Euro-Drug Emergencies Network (Euro-DEN) ED presentations with acute toxicity related to the misuse of prescription medicines Professor Paul.

Atrial Fibrillation.

Trials and Tribulations in VTE: How Do Real-World Data Fit In?

Patients with Atrial Fibrillation Switching Emphasis from stroke prevention to stroke and hemorrhage prevention. Michael D. Ezekowitz, MBChB, DPhil, FACC,

Which NOAC and When for Stroke Prevention in AF?

Real-World Data in Cardiology: Focus on Atrial Fibrillation

Parents with Disabilities Pilot Program Update Community Advisory Committee Tuesday, September 10, 2019.

What's New in NOACs in AF?.

Causes and predictors of short, intermediate and long-term mortality in patients with coronary artery disease M. Zeitouni, N. Procopi, O. Barthélémy, Q.

Presentation transcript:

Anticoagulation and AF: Emerging Insights Professor the Lord Kakkar Thrombosis Research Institute and University College London

Register of Interests for Ajay Kakkar Research Support/P.I. Bayer HealthCare, Sanofi-Aventis, Boehringer Ingelheim, Pfizer, Bristol–Myers Squibb, Eisai Employee N/A Consultant Bayer HealthCare, Sanofi-Aventis, Boehringer Ingelheim, Pfizer, Bristol–Myers Squibb, Eisai, Novartis, Adventrix, Daiichi Sankyo, Shire Major Stockholder Speakers Bureau Honoraria Bayer HealthCare, Sanofi-Aventis, Boehringer Ingelheim, Pfizer, Bristol–Myers Squibb, Eisai, GSK Scientific Advisory Board Bayer HealthCare, Sanofi-Aventis, Boehringer Ingelheim, Pfizer, Bristol–Myers Squibb, Eisai, Novartis, Daiichi Sankyo

The Global Anticoagulant Registry in the Field: Ongoing representative, worldwide outcomes research programme Independent academic research initiative 55,000 newly-diagnosed AF patients in 34 countries Randomized selection of sites representative of national AF care settings Unselected prospective patients enrolled consecutively Long-term follow-up (minimum of 2 years, up to 8 years) 5 sequential prospective cohorts Extensive monitoring (20% of CRFs) 2010 2011 2012 2013 2014 2015 2016 2017 2018 Cohort 1 Dec-09 Oct-13 Jun-18 Cohort 2 Oct-11 Jun-15 Recruitment Cohort 3 Jun-13 Jun-16 Minimum follow-up Cohort 4 Aug-14 Jun-17 Extended follow-up Cohort 5 Jul-15

The Global Anticoagulant Registry in the Field: Already one of the largest outcomes research programmes in AF 34,205 AF patients recruited in 34 countries 29,117 prospective patients Cohort 3 recruitment completed July 2014 (n=11,405) Cohort 4 recruitment opened August 2014 (n=456) 2010 2011 2012 2013 2014 2015 2016 2017 2018 Cohort 1 Dec-09 Oct-13 Jun-18 Cohort 2 Oct-11 Jun-15 Recruitment Cohort 3 Jun-13 Jun-16 Minimum follow-up Cohort 4 Aug-14 Jun-17 Extended follow-up Cohort 5 Jul-15

Antithrombotic prescribing patterns in Garfield-AF Dec 09-Oct 11 Oct 11-Jun 13 Jun 13-Jun 14 Dec 09-Jun14 Preliminary data 30 June 2014 N=10,278 N=11,557 N=9831 N=31,666

The use of NOACs has increased Dec 09-Oct 11 Oct 11-Jun 13 Jun 13-Jun 14 Dec 09-Jun13 Preliminary data 30 June 2014

Acknowledgements This research programme would not be possible without the hard work and dedication of the: Steering Committee National Coordinator Council Garfield-AF Investigators

Anticoagulation and AF: Emerging Insights Agenda Understanding risk, Professor Dan Atar The role of anticoagulants, Professor Keith Fox Preventing a second stroke, Professor John Camm Lessons beyond AF, Professor Samuel Z Goldhaber Future challenges, Professor Alexander GG Turpie Panel discussion: Stroke prevention in AF 2014, Case Presenter: Professor Sylvia Haas Discussant: Dr Bernard J Gersh Closing remarks, Professor Jean-Pierre Bassand